Maintenance Treatment
459 articles
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Maintenance Chemotherapy for Stable Metastatic Pancreatic Cancer
A clinical trial tests the diabetes drug metformin and transplant rejection preventative rapamycin to act as maintenance chemotherapy for pancreatic cancer.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
I Feel Very Lucky!
Because of her early career experience as an oncology nurse, Ann Jaffe wanted to participate in a clinical trial.
Time and Hope
Rose farmer Michael Francis wanted more time with his family, so he joined a clinical trial to treat his stage III pancreatic cancer.
Determined to Win
After a metastatic pancreatic cancer diagnosis, Linda Chambless sought a second opinion, which led her to a clinical trial.
Gift of Another Breath
Angella Dixon-Watson is grateful for her treatment team and the support of her family as she faced pancreatic neuroendocrine cancer.
A Life-Saving, Life-Changing Diagnosis
Randi C. Ervin’s primary care doctor suspected she had something more than prediabetes. Testing showed pancreatic neuroendocrine cancer.
Molecular Sequencing Leads to Customized Treatment
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.
The Relatively New Procedure of Irreversible Electroporation Has Given Me Time
When chemotherapy and radiation stopped working, Leslie Wineberg was glad to qualify for irreversible electroporation (IRE).
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.